ARTICLE | Clinical News
Zynerba refocusing on CBD gel following failed patch readout
July 13, 2018 6:55 PM UTC
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a Phase I trial in 60 healthy volunteers. The company had planned to start a Phase II trial this year of ZYN001 to treat Tourette’s syndrome.
The company, which had $52.1 million in cash at March 31, said it expects the shift in focus to extend its runway to 2H19...
BCIQ Company Profiles
BCIQ Target Profiles